Advisory Services Network LLC Sells 301 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Advisory Services Network LLC trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.6% during the fourth quarter, Holdings Channel reports. The firm owned 6,268 shares of the biopharmaceutical company’s stock after selling 301 shares during the quarter. Advisory Services Network LLC’s holdings in Alnylam Pharmaceuticals were worth $1,475,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Allworth Financial LP boosted its position in Alnylam Pharmaceuticals by 6.8% during the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 38 shares during the period. Nixon Peabody Trust Co. lifted its stake in shares of Alnylam Pharmaceuticals by 1.9% during the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after buying an additional 43 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 47 shares during the last quarter. Nwam LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 5.8% during the 4th quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 50 shares during the period. Finally, National Bank of Canada FI grew its stake in Alnylam Pharmaceuticals by 9.0% in the 4th quarter. National Bank of Canada FI now owns 668 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 55 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Up 5.1 %

ALNY stock opened at $237.77 on Friday. The stock has a market capitalization of $30.93 billion, a P/E ratio of -109.57 and a beta of 0.30. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The firm has a 50-day moving average price of $253.20 and a 200-day moving average price of $258.37. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Activity

In other news, Director Phillip A. Sharp sold 11,250 shares of the company’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CMO Pushkal Garg sold 1,548 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,017,271.63. This trade represents a 11.44 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,234 shares of company stock worth $19,958,097. Insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several research reports. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $280.00 to $328.00 in a research report on Monday, March 24th. Needham & Company LLC reissued a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday. Morgan Stanley decreased their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating on the stock in a report on Friday. Stifel Nicolaus lifted their target price on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a report on Monday, March 31st. Finally, Scotiabank boosted their target price on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a “sector outperform” rating in a research report on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $315.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.